Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 462 entries
Sorted by: Best Match Show Resources per page
Oncotype DX and Prosigna in breast cancer patients: A comparison study.

Cancer treatment and research communications

Abdelhakam DA, Hanna H, Nassar A.
PMID: 33444922
Cancer Treat Res Commun. 2021;26:100306. doi: 10.1016/j.ctarc.2021.100306. Epub 2021 Jan 07.

BACKGROUND: Oncotype Dx® (ODX) is the most used prognostic and predictive assay for ER + breast cancer (BCa) and is categorized into low (< 18), intermediate (18 to 30), or high (≥31) risk of recurrence. Prosigna® is a prognostic...

Cite
Abdelhakam DA, Hanna H, Nassar A. Oncotype DX and Prosigna in breast cancer patients: A comparison study. Cancer Treat Res Commun. 2021;26:100306doi: 10.1016/j.ctarc.2021.100306.
Abdelhakam, D. A., Hanna, H., & Nassar, A. (2021). Oncotype DX and Prosigna in breast cancer patients: A comparison study. Cancer treatment and research communications, 26100306. https://doi.org/10.1016/j.ctarc.2021.100306
Abdelhakam, Dina A, et al. "Oncotype DX and Prosigna in breast cancer patients: A comparison study." Cancer treatment and research communications vol. 26 (2021): 100306. doi: https://doi.org/10.1016/j.ctarc.2021.100306
Abdelhakam DA, Hanna H, Nassar A. Oncotype DX and Prosigna in breast cancer patients: A comparison study. Cancer Treat Res Commun. 2021;26:100306. doi: 10.1016/j.ctarc.2021.100306. Epub 2021 Jan 07. PMID: 33444922.
Copy Download .nbib Format: NLM
The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters.

Cancer treatment and research communications

Uygur MM, Gümüş M.
PMID: 34082362
Cancer Treat Res Commun. 2021;28:100402. doi: 10.1016/j.ctarc.2021.100402. Epub 2021 May 24.

BACKGROUND: We aimed to evaluate the association of serum carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA 15-3) levels with clinicopathological parameters in patients with breast cancer (BC) and their efficiency for the prediction of recurrence.METHODS: The records of...

Cite
Uygur MM, Gümüş M. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters. Cancer Treat Res Commun. 2021;28:100402doi: 10.1016/j.ctarc.2021.100402.
Uygur, M. M., & Gümüş, M. (2021). The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters. Cancer treatment and research communications, 28100402. https://doi.org/10.1016/j.ctarc.2021.100402
Uygur, Meliha Melin, and Gümüş, Mahmut. "The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters." Cancer treatment and research communications vol. 28 (2021): 100402. doi: https://doi.org/10.1016/j.ctarc.2021.100402
Uygur MM, Gümüş M. The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters. Cancer Treat Res Commun. 2021;28:100402. doi: 10.1016/j.ctarc.2021.100402. Epub 2021 May 24. PMID: 34082362.
Copy Download .nbib Format: NLM
Predictive factors associated with radiation dermatitis in breast cancer.

Cancer treatment and research communications

Behroozian T, Milton L, Li N, Zhang L, Lou J, Karam I, Wronski M, McKenzie E, Mawdsley G, Razvi Y, Chow E, Ruschin M.
PMID: 34082363
Cancer Treat Res Commun. 2021;28:100403. doi: 10.1016/j.ctarc.2021.100403. Epub 2021 May 26.

PURPOSE: Radiation dermatitis (RD) is a side effect that frequently arises during radiotherapy (RT) in breast cancer patients. The present study investigates possible predictive factors of RD, as well as the use of skin treatments to manage symptoms.METHODS: Demographic...

Cite
Behroozian T, Milton L, Li N, et al. Predictive factors associated with radiation dermatitis in breast cancer. Cancer Treat Res Commun. 2021;28:100403doi: 10.1016/j.ctarc.2021.100403.
Behroozian, T., Milton, L., Li, N., Zhang, L., Lou, J., Karam, I., Wronski, M., McKenzie, E., Mawdsley, G., Razvi, Y., Chow, E., & Ruschin, M. (2021). Predictive factors associated with radiation dermatitis in breast cancer. Cancer treatment and research communications, 28100403. https://doi.org/10.1016/j.ctarc.2021.100403
Behroozian, Tara, et al. "Predictive factors associated with radiation dermatitis in breast cancer." Cancer treatment and research communications vol. 28 (2021): 100403. doi: https://doi.org/10.1016/j.ctarc.2021.100403
Behroozian T, Milton L, Li N, Zhang L, Lou J, Karam I, Wronski M, McKenzie E, Mawdsley G, Razvi Y, Chow E, Ruschin M. Predictive factors associated with radiation dermatitis in breast cancer. Cancer Treat Res Commun. 2021;28:100403. doi: 10.1016/j.ctarc.2021.100403. Epub 2021 May 26. PMID: 34082363.
Copy Download .nbib Format: NLM
Sellar plasmacytoma with massive bleeding during surgery.

Cancer treatment and research communications

Lee DH, Kim JH, Jang WY, Jung S, Lim SC.
PMID: 34922217
Cancer Treat Res Commun. 2021 Dec 12;30:100499. doi: 10.1016/j.ctarc.2021.100499. Epub 2021 Dec 12.

Plasmacytoma in the sellar region is an extremely rare occurrence. Sellar plasmacytoma is often difficult to differentiate from pituitary tumors both clinically and radiologically. The occurrence of cranial nerve palsy, the preservation of pituitary hormone function, the presence of...

Cite
Lee DH, Kim JH, Jang WY, et al. Sellar plasmacytoma with massive bleeding during surgery. Cancer Treat Res Commun. 2021;30:100499doi: 10.1016/j.ctarc.2021.100499.
Lee, D. H., Kim, J. H., Jang, W. Y., Jung, S., & Lim, S. C. (2021). Sellar plasmacytoma with massive bleeding during surgery. Cancer treatment and research communications, 30100499. https://doi.org/10.1016/j.ctarc.2021.100499
Lee, Dong Hoon, et al. "Sellar plasmacytoma with massive bleeding during surgery." Cancer treatment and research communications vol. 30 (2021): 100499. doi: https://doi.org/10.1016/j.ctarc.2021.100499
Lee DH, Kim JH, Jang WY, Jung S, Lim SC. Sellar plasmacytoma with massive bleeding during surgery. Cancer Treat Res Commun. 2021 Dec 12;30:100499. doi: 10.1016/j.ctarc.2021.100499. Epub 2021 Dec 12. PMID: 34922217.
Copy Download .nbib Format: NLM
Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas.

Cancer treatment and research communications

Naso JR, Banyi N, Al-Hashami Z, Zhu J, Wang G, Ionescu DN, Ho C.
PMID: 33770662
Cancer Treat Res Commun. 2021;27:100353. doi: 10.1016/j.ctarc.2021.100353. Epub 2021 Mar 18.

INTRODUCTION: PD-L1 expression may be used as a biomarker predictive of non-small cell lung carcinoma (NSCLC) response to PD-L1 inhibitor treatment. Spatial and temporal heterogeneity in PD-L1 expression and variation in PD-L1 test interpretation may contribute to differences in...

Cite
Naso JR, Banyi N, Al-Hashami Z, et al. Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas. Cancer Treat Res Commun. 2021;27:100353doi: 10.1016/j.ctarc.2021.100353.
Naso, J. R., Banyi, N., Al-Hashami, Z., Zhu, J., Wang, G., Ionescu, D. N., & Ho, C. (2021). Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas. Cancer treatment and research communications, 27100353. https://doi.org/10.1016/j.ctarc.2021.100353
Naso, Julia R, et al. "Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas." Cancer treatment and research communications vol. 27 (2021): 100353. doi: https://doi.org/10.1016/j.ctarc.2021.100353
Naso JR, Banyi N, Al-Hashami Z, Zhu J, Wang G, Ionescu DN, Ho C. Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas. Cancer Treat Res Commun. 2021;27:100353. doi: 10.1016/j.ctarc.2021.100353. Epub 2021 Mar 18. PMID: 33770662.
Copy Download .nbib Format: NLM
Vibration Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer - a pilot study.

Cancer treatment and research communications

Marstrand SD, Buch-Larsen K, Andersson M, Jensen LT, Schwarz P.
PMID: 34186438
Cancer Treat Res Commun. 2021;28:100426. doi: 10.1016/j.ctarc.2021.100426. Epub 2021 Jun 17.

PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a recognized adverse effect of standard (neo)adjuvant chemotherapy in breast cancer (BC) treatment. However, there is no consensus on a validated method for assessing CIPN. Heart rate variability (HRV) and vibration perception threshold...

Cite
Marstrand SD, Buch-Larsen K, Andersson M, et al. Vibration Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer - a pilot study. Cancer Treat Res Commun. 2021;28:100426doi: 10.1016/j.ctarc.2021.100426.
Marstrand, S. D., Buch-Larsen, K., Andersson, M., Jensen, L. T., & Schwarz, P. (2021). Vibration Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer - a pilot study. Cancer treatment and research communications, 28100426. https://doi.org/10.1016/j.ctarc.2021.100426
Marstrand, Simone Diedrichsen, et al. "Vibration Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer - a pilot study." Cancer treatment and research communications vol. 28 (2021): 100426. doi: https://doi.org/10.1016/j.ctarc.2021.100426
Marstrand SD, Buch-Larsen K, Andersson M, Jensen LT, Schwarz P. Vibration Perception Threshold and Heart Rate Variability as methods to assess chemotherapy-induced neuropathy in women with breast cancer - a pilot study. Cancer Treat Res Commun. 2021;28:100426. doi: 10.1016/j.ctarc.2021.100426. Epub 2021 Jun 17. PMID: 34186438.
Copy Download .nbib Format: NLM
A scoping review of literature: What has been studied about adolescents and young adults (AYAs) with cancer?.

Cancer treatment and research communications

Telles CM.
PMID: 33545568
Cancer Treat Res Commun. 2021;27:100316. doi: 10.1016/j.ctarc.2021.100316. Epub 2021 Jan 29.

PURPOSE: To map, organize and analyze the articles published in the last five years about AYAs with cancer.METHODS: CAPES database and Google Scholar were searched to identify relevant studies from 2015 to February 2020. Eligible articles included empirical or...

Cite
Telles CM. A scoping review of literature: What has been studied about adolescents and young adults (AYAs) with cancer?. Cancer Treat Res Commun. 2021;27:100316doi: 10.1016/j.ctarc.2021.100316.
Telles, C. M. (2021). A scoping review of literature: What has been studied about adolescents and young adults (AYAs) with cancer?. Cancer treatment and research communications, 27100316. https://doi.org/10.1016/j.ctarc.2021.100316
Telles, Camila M. "A scoping review of literature: What has been studied about adolescents and young adults (AYAs) with cancer?." Cancer treatment and research communications vol. 27 (2021): 100316. doi: https://doi.org/10.1016/j.ctarc.2021.100316
Telles CM. A scoping review of literature: What has been studied about adolescents and young adults (AYAs) with cancer?. Cancer Treat Res Commun. 2021;27:100316. doi: 10.1016/j.ctarc.2021.100316. Epub 2021 Jan 29. PMID: 33545568.
Copy Download .nbib Format: NLM
Impact of high-risk features for stage II adenocarcinoma of the appendix.

Cancer treatment and research communications

Akce M, Zakka K, Penley M, Jiang R, Khalil L, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF.
PMID: 33609973
Cancer Treat Res Commun. 2021;27:100329. doi: 10.1016/j.ctarc.2021.100329. Epub 2021 Feb 04.

BACKGROUND: Clinico-pathological high-risk features are frequently utilized in adjuvant chemotherapy (AC) decisions in stage II colorectal cancer and their utility in stage II appendiceal adenocarcinoma (AA) is not established. The aim of this study is to determine the impact...

Cite
Akce M, Zakka K, Penley M, et al. Impact of high-risk features for stage II adenocarcinoma of the appendix. Cancer Treat Res Commun. 2021;27:100329doi: 10.1016/j.ctarc.2021.100329.
Akce, M., Zakka, K., Penley, M., Jiang, R., Khalil, L., Alese, O. B., Shaib, W. L., Wu, C., Behera, M., & El-Rayes, B. F. (2021). Impact of high-risk features for stage II adenocarcinoma of the appendix. Cancer treatment and research communications, 27100329. https://doi.org/10.1016/j.ctarc.2021.100329
Akce, Mehmet, et al. "Impact of high-risk features for stage II adenocarcinoma of the appendix." Cancer treatment and research communications vol. 27 (2021): 100329. doi: https://doi.org/10.1016/j.ctarc.2021.100329
Akce M, Zakka K, Penley M, Jiang R, Khalil L, Alese OB, Shaib WL, Wu C, Behera M, El-Rayes BF. Impact of high-risk features for stage II adenocarcinoma of the appendix. Cancer Treat Res Commun. 2021;27:100329. doi: 10.1016/j.ctarc.2021.100329. Epub 2021 Feb 04. PMID: 33609973.
Copy Download .nbib Format: NLM
Tamoxifen. A treatment for meningioma?.

Cancer treatment and research communications

Champeaux-Depond C, Weller J.
PMID: 33647870
Cancer Treat Res Commun. 2021;27:100343. doi: 10.1016/j.ctarc.2021.100343. Epub 2021 Feb 24.

BACKGROUND: No large-scale study evaluating the usefulness of tamoxifen after meningioma surgery has been undertaken.METHODS: We processed the French Système National des Données de Santé (SNDS) database using an algorithm combining the type of surgical procedure and the International...

Cite
Champeaux-Depond C, Weller J. Tamoxifen. A treatment for meningioma?. Cancer Treat Res Commun. 2021;27:100343doi: 10.1016/j.ctarc.2021.100343.
Champeaux-Depond, C., & Weller, J. (2021). Tamoxifen. A treatment for meningioma?. Cancer treatment and research communications, 27100343. https://doi.org/10.1016/j.ctarc.2021.100343
Champeaux-Depond, Charles, and Weller, Joconde. "Tamoxifen. A treatment for meningioma?." Cancer treatment and research communications vol. 27 (2021): 100343. doi: https://doi.org/10.1016/j.ctarc.2021.100343
Champeaux-Depond C, Weller J. Tamoxifen. A treatment for meningioma?. Cancer Treat Res Commun. 2021;27:100343. doi: 10.1016/j.ctarc.2021.100343. Epub 2021 Feb 24. PMID: 33647870.
Copy Download .nbib Format: NLM
The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial.

Cancer treatment and research communications

Wang J, Yu X, Barnes G, Leaw S, Bao Y, Tang B.
PMID: 34952253
Cancer Treat Res Commun. 2021 Dec 17;30:100501. doi: 10.1016/j.ctarc.2021.100501. Epub 2021 Dec 17.

BACKGROUND: This study assessed the effects of adding tislelizumab to first-line standard-of- care chemotherapy on the health-related quality of life (HRQoL) of patients with advanced squamous non-small cell lung cancer (sq-NSCLC).PATIENTS AND METHODS: Patients in this open-label, multicenter, phase...

Cite
Wang J, Yu X, Barnes G, et al. The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer Treat Res Commun. 2021;30:100501doi: 10.1016/j.ctarc.2021.100501.
Wang, J., Yu, X., Barnes, G., Leaw, S., Bao, Y., & Tang, B. (2021). The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer treatment and research communications, 30100501. https://doi.org/10.1016/j.ctarc.2021.100501
Wang, J, et al. "The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial." Cancer treatment and research communications vol. 30 (2021): 100501. doi: https://doi.org/10.1016/j.ctarc.2021.100501
Wang J, Yu X, Barnes G, Leaw S, Bao Y, Tang B. The effects of tislelizumab plus chemotherapy as first-line treatment on health-related quality of life of patients with advanced squamous non-small cell lung cancer: Results from a phase 3 randomized clinical trial. Cancer Treat Res Commun. 2021 Dec 17;30:100501. doi: 10.1016/j.ctarc.2021.100501. Epub 2021 Dec 17. PMID: 34952253.
Copy Download .nbib Format: NLM
Druggable genetic targets in endometrial cancer.

Cancer treatment and research communications

Lehrer S, Rheinstein PH.
PMID: 34933203
Cancer Treat Res Commun. 2021 Dec 17;30:100502. doi: 10.1016/j.ctarc.2021.100502. Epub 2021 Dec 17.

BACKGROUND: FBXW7 is frequently somatically mutated in grade 3 endometrioid endometrial cancers (G3EECs) and serous endometrial cancers (SECs), high-risk cancers associated with poor prognosis. CRISPR-edited cell lines identified the proteomic and phosphoproteomic effects of FBXW7 mutation in 3 high-risk...

Cite
Lehrer S, Rheinstein PH. Druggable genetic targets in endometrial cancer. Cancer Treat Res Commun. 2021;30:100502doi: 10.1016/j.ctarc.2021.100502.
Lehrer, S., & Rheinstein, P. H. (2021). Druggable genetic targets in endometrial cancer. Cancer treatment and research communications, 30100502. https://doi.org/10.1016/j.ctarc.2021.100502
Lehrer, Steven, and Rheinstein, Peter H. "Druggable genetic targets in endometrial cancer." Cancer treatment and research communications vol. 30 (2021): 100502. doi: https://doi.org/10.1016/j.ctarc.2021.100502
Lehrer S, Rheinstein PH. Druggable genetic targets in endometrial cancer. Cancer Treat Res Commun. 2021 Dec 17;30:100502. doi: 10.1016/j.ctarc.2021.100502. Epub 2021 Dec 17. PMID: 34933203.
Copy Download .nbib Format: NLM
Sellar plasmacytoma with massive bleeding during surgery.

Cancer treatment and research communications

Lee DH, Kim JH, Jang WY, Jung S, Lim SC.
PMID: 34922217
Cancer Treat Res Commun. 2021 Dec 12;30:100499. doi: 10.1016/j.ctarc.2021.100499. Epub 2021 Dec 12.

Plasmacytoma in the sellar region is an extremely rare occurrence. Sellar plasmacytoma is often difficult to differentiate from pituitary tumors both clinically and radiologically. The occurrence of cranial nerve palsy, the preservation of pituitary hormone function, the presence of...

Cite
Lee DH, Kim JH, Jang WY, et al. Sellar plasmacytoma with massive bleeding during surgery. Cancer Treat Res Commun. 2021;30:100499doi: 10.1016/j.ctarc.2021.100499.
Lee, D. H., Kim, J. H., Jang, W. Y., Jung, S., & Lim, S. C. (2021). Sellar plasmacytoma with massive bleeding during surgery. Cancer treatment and research communications, 30100499. https://doi.org/10.1016/j.ctarc.2021.100499
Lee, Dong Hoon, et al. "Sellar plasmacytoma with massive bleeding during surgery." Cancer treatment and research communications vol. 30 (2021): 100499. doi: https://doi.org/10.1016/j.ctarc.2021.100499
Lee DH, Kim JH, Jang WY, Jung S, Lim SC. Sellar plasmacytoma with massive bleeding during surgery. Cancer Treat Res Commun. 2021 Dec 12;30:100499. doi: 10.1016/j.ctarc.2021.100499. Epub 2021 Dec 12. PMID: 34922217.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 462 entries